Which is the quickest weight loss injection available in the UK?

Which injection produces results faster, and by how much?

Both Mounjaro and Wegovy begin working from the first dose, but describing one as dramatically quicker than the other in the early weeks is an overstatement. The clearest difference between them is in the total weight lost rather than the pace at which it arrives.

In the SURMOUNT-1 trial, adults taking tirzepatide at the 15mg maintenance dose lost an average of around 20–21% of their body weight over 72 weeks, as reported in the New England Journal of Medicine. The STEP 1 trial for semaglutide at 2.4mg showed roughly 15% average loss over 68 weeks. The SURMOUNT-5 head-to-head trial, published in 2025, confirmed that tirzepatide produced greater average weight reduction than semaglutide 2.4mg in a direct comparison.

What that means practically: both medicines start reducing appetite early, but the gap in outcomes grows over the full course of treatment rather than appearing in week one or two. If your goal is the largest total reduction, the evidence points toward tirzepatide — but which medicine suits your health profile is a clinical decision, not a consumer one.

You can read more about how the timeline unfolds in our guide on how quickly weight loss injections work.

Does the starting dose affect how soon results appear?

This is a question worth taking seriously, because the titration schedule matters more than most people expect. Both Mounjaro and Wegovy begin at a low starter dose (2.5mg for tirzepatide) whose job is to let your body adjust rather than to drive weight loss. Jumping ahead to a higher dose isn't faster in practice; it tends to cause worse nausea and may mean stepping back down, which delays progress.

The NHS tirzepatide page describes the escalation schedule that a prescriber follows, with dose increases typically every four weeks. Most people reach a meaningful therapeutic dose somewhere between months two and four. That's when the appetite-reduction effect becomes most consistent.

Some patients notice changes in hunger and portion size within the first two weeks even at the starter dose. Others feel little different until the dose rises. Both experiences are normal. The right response to slow early progress is a conversation with your prescriber, not self-adjusting the dose or the timing.

If cost is part of your thinking at this stage, the cost context for weight loss injections is worth reading before you make any assumptions about what different providers include in their pricing.

Are there any genuinely faster alternatives to these injections?

Not among licensed UK weight management medicines. Orlistat (a capsule that blocks dietary fat absorption) is available without some of the same access barriers, but its average results are considerably more modest and it works through a completely different mechanism. It is not an injection and does not suppress appetite.

You may have read about various weight loss injections by different names online. Saxenda (liraglutide) is another GLP-1 medicine licensed for weight management in the UK, but the clinical trial data shows lower average results than either Mounjaro or Wegovy. Ozempic, despite its high profile, is licensed for type 2 diabetes, not weight loss, and should not be presented as a weight management medicine by any legitimate provider.

The honest answer is that there is no shortcut within the licensed options. What you can control is removing unnecessary delays: using a regulated online pharmacy with same-day clinical review means treatment can be prescribed and dispatched quickly once you're assessed as suitable. The pharmacology still takes the time it takes.

What actually shapes how quickly someone loses weight on these injections?

Clinical trials report averages across large groups. Your result sits somewhere in the distribution around that average, shaped by factors a trial can't control for individually. Starting BMI matters: someone starting at a higher weight tends to see larger absolute losses, though percentage loss can be similar. Dose reached is significant, patients who tolerate the higher doses consistently tend to see more change over time.

Diet quality alongside treatment is frequently underestimated. These medicines reduce appetite but do not replace the benefit of adequate protein, enough fibre and staying hydrated. Muscle loss during rapid weight reduction is a real concern; strength-based activity helps preserve it.

There are also less obvious factors. A question our prescribers hear regularly is whether a patient's other medicines might interact with treatment. If you have epilepsy, for instance, the interaction between weight loss injections and epilepsy medicines is something to discuss carefully with your clinician before starting.

Our clinical team reviews every consultation individually (same day, on a working day) before any prescription is issued. If you'd like to discuss which option fits your situation, check your eligibility with our prescribers.